Behind The Deal: Agentis Longevity Expands Access to Life-Changing Longevity Care With Mantality Acquisition

by | Mar 18, 2025

Agentis Longevity, a Shore Capital Partners-backed healthcare platform, announced its acquisition of Mantality, a provider of hormone replacement therapy and medical weight loss services. The deal, which closed recently, was facilitated by Agenda Health, an Austin, Texas-based M&A advisory firm focused on healthcare.

Chesterfield, Missouri-based Mantality runs clinics across the Midwest, including Missouri, Iowa, Wisconsin, Nebraska, Michigan, Ohio and Pennsylvania. Agentis Longevity, based in Florida, is creating a network of accessible, high-quality longevity practices.

Longevity care focuses on extending healthy lifespans through personalized medical interventions, such as hormone optimization and weight management. It aims to enhance quality of life by addressing age-related decline with evidence-based treatments. Historical deal data for longevity care is light since it’s a new and rapidly growing field gaining significance as a specialized approach to aging.

We spoke with Jimmy St Louis, CEO of Agentis Longevity, and Alex Veach, Director of Transaction Services at Agenda Health, to explore what drove this deal and its place in the specialized healthcare market.

Mantality caught Agentis Longevity’s eye as a leader in patient-first testosterone replacement therapy (TRT), a treatment increasingly sought after as upwards of 5 million men in the United States deal with hypogonadism, per the Cleveland Clinic. St Louis saw the Mantality model as a fit for his vision.

“Agentis Longevity is a healthcare platform focused on setting the standard of care for and democratizing access to longevity-based healthcare through our partnerships with best-in-class physicians, partners, operators and other healthcare experts,” said St Louis. “Our partnership with Shore Capital will accelerate achieving our objective to first acquire best-in-class longevity practices and then to share best practices to create an accessible and affordable solution for patients seeking to live longer, healthier, more fulfilling lives.”

Agenda Health kicked off the process after targeting Mantality for its sector potential. The firm acted as the exclusive sell-side advisor to Mantality Health in the transaction.

“Agenda facilitated a competitive market process for Mantality that produced several bids from interested parties,” said Veach. “From there, it became clear that Shore Capital had the strongest alignment with Mantality ownership. There were no significant challenges over the course of diligence; both parties worked together smoothly towards closing.”

Agentis Longevity plans to leverage Shore’s deep healthcare playbook to build on Mantality’s strengths while scaling its reach. St Louis aims to refine care standards with this foothold.

“Mantality practices medicine in a manner that puts the patients first, with a focus on outcomes through measuring data,” said St Louis. “They’ve got a great patient services delivery model with frequent hormone panels and testing, and the interactions that the providers have directly with the patients, in our opinion, is best in class.”

Kevin Meuret, Founder of Mantality and the seller in the transaction, echoed this focus on patient care while highlighting the deal’s broader impact.

“Agentis Longevity’s acquisition of Mantality transforms us from a regional leader in TRT treatment into broader spectrum men’s health, leveraging a streamlined growth playbook to expand our reach efficiently while prioritizing exceptional patient care,” Meuret said. “With access to cutting-edge treatments and robust operational systems, we can now offer innovative, high-quality services, empowering men to live healthier, more vibrant lives. This was the best move we could have made for our clients and our company.”

The deal progressed smoothly with no major obstacles. Both sides shared a clear focus. According to Veach, the key factors that made the deal successful were strong cultural alignment between the two parties and strong tailwinds in the sector.

Agentis Longevity’s move aligns with growing interest in longevity-focused healthcare. Demand for hormone therapy and weight loss services is climbing, fueling M&A in specialized care. The global HRT market hit $37.4 billion in 2024, per Precedence Research, with a projected 6% CAGR through 2034 as aging populations and chronic conditions drive need. Private equity sees an opportunity in this space, with Veach highlighting the “surge in bids” for Mantality as proof of the sector’s allure.

“Agenda has been very excited about the broader Longevity sector for a long time now, which prompted our initial outreach to Mantality ownership,” said Veach. “With the increasing demand across the country for these services that will support continued growth in the sector, we see a tremendous opportunity for private equity to build compelling platforms. The results of our process for Mantality proved that thesis – Agenda looks forward to continuing to partner with owners in health and wellness and longevity services.”

Broader insurance acceptance and growing patient awareness are accelerating this trend. With the acquisition of Mantality, St Louis sees an opportunity to democratize access, challenging the perception that longevity care is a niche luxury reserved for the elite.

“Typically in longevity healthcare, people believe it to be an expensive treatment offering only for the wealthy,” said St Louis. “My goal is to help make this accessible to people that may not have necessarily had access to these types of modalities in the past through a more robust patient journey in a staged process that allows us to build trust and help patients understand the efficacy of our treatments.”

Mantality’s patient data comes from its hormone therapy and weight loss services across Midwest clinics, a key asset as St Louis plans a national expansion. The deal hands Agentis a network of providers and a window into patient trends.

 “Our first move with Mantality is to create consistent protocols across the board to extend services,” said St Louis. “They have a large number of great providers, thousands of very happy patients and lots of great data, so this deal allows us to gain a deep understanding of what motivates the patients, what they’re looking for and what their demographics are.”

Mantality’s track record in building out its clinics with a steady, measured pace stood out to Agentis. St Louis aims to target more practices with this kind of edge, building a network that sticks to real outcomes. The plan is to turn those lessons into a working model.

“This is the first of many partnerships that allows us to really establish what the standard of care should look like, and what quality of care should look like within this industry,” said St Louis. “I believe that the industry needs it.”

Mantality’s provider network gives Agentis a head start in scaling care delivery. St Louis plans to use its patient base to drive expansion and raise awareness. He sees Mantality’s Midwest footprint as a testing ground for broader reach. The focus will be on refining what works and rolling it out to new markets.

“We’re very proud to have partnered with Mantality, and this partnership has given us the confidence that we can work to continue to set the standard of care and educate a marketplace all over the country that may not have had access to this before,” said St Louis.

For other news on the home health market, visit the LevinPro HC platform. Check out some of our recent interviews conducted with the Agenda Health team: